Bevacizumab Plus Direct Oral Anticoagulant Therapy in Ovarian Cancer Patients with Distal Deep Vein Thrombosis

2019 ◽  
Vol 39 (4) ◽  
pp. 395-400 ◽  
Author(s):  
Shinichi Komiyama ◽  
Masaru Nagashima ◽  
Tomoko Taniguchi ◽  
Takayuki Rikitake ◽  
Mineto Morita
Keyword(s):  
Ovarian Cancer ◽  
Deep Vein Thrombosis ◽  
Cancer Patients ◽  
Anticoagulant Therapy ◽  
Oral Anticoagulant ◽  
Oral Anticoagulant Therapy ◽  
Direct Oral Anticoagulant ◽  
Vein Thrombosis ◽  
Distal Deep Vein Thrombosis ◽  
Deep Vein

Controlled Trial of the Sequential Use of Streptokinase and Ancrod in the Treatment of Deep Vein Thrombosis of Lower Limb

1977 ◽  
Vol 37 (02) ◽  
pp. 222-232 ◽  
Author(s):  
D. A Tibbutt ◽  
C. N Chesterman ◽  
E. W Williams ◽  
T Faulkner ◽  
A. A Sharp
Keyword(s):  
Deep Vein Thrombosis ◽  
Clinical Improvement ◽  
Anticoagulant Therapy ◽  
Lower Limb ◽  
Oral Anticoagulant ◽  
Controlled Trial ◽  
Oral Anticoagulant Therapy ◽  
Control Group ◽  
Vein Thrombosis ◽  
Deep Vein

SummaryTreatment with streptokinase (‘Kabikinase’) was given to 26 patients with venographically confirmed deep vein thrombosis extending into the popliteal vein or above. Treatment was continued for 4 days and the patients were allocated randomly to oral anticoagulant therapy or a course of treatment with ancrod (‘Arvin’) for 6 days followed by oral anticoagulant therapy. The degree of thrombolysis as judged by further venographic examination at 10 days was not significantly different between the 2 groups. The majority of patients showed clinical improvement but there was no appreciable difference between the groups at 3 and 6 months. Haemorrhagic complications were a more serious problem during the period of treatment with ancrod than during the equivalent period in the control group.

Duration of Oral Anticoagulant Therapy after Proximal Deep Vein Thrombosis: a Decision Analysis

1994 ◽  
Vol 71 (03) ◽  
pp. 286-291 ◽  
Author(s):  
François P Sarasin ◽  
Henri Bounameaux
Keyword(s):  
Deep Vein Thrombosis ◽  
Decision Analysis ◽  
Anticoagulant Therapy ◽  
Oral Anticoagulant ◽  
Oral Anticoagulant Therapy ◽  
Oral Anticoagulants ◽  
Bleeding Risk ◽  
Lower Limbs ◽  
Vein Thrombosis ◽  
Deep Vein

SummaryThe optimal duration of oral anticoagulant therapy following proximal deep vein thrombosis (DVT) in the lower limbs remains controversial. To compare the risk benefit tradeoffs for different treatment durations (6 to 24 weeks) we constructed a Markov-based decision analysis model which explicitly balances the time-dependent declining risk of recurrent thrombosis and pulmonary embolism against the risk of major hemorrhagic complications. Specifically, we determined the threshold below which the risk of recurrent DVT exceeds the risk of major hemorrhage if anticoagulant therapy is discontinued, and above which the benefits provided by oral anticoagulants are outweighed by their risk.Our model shows that for patients with a low hemorrhagic risk (0.5%/month), the benefit yielded by oral anticoagulants breaks off beyond the 4th month of therapy, while patients with moderate (1%/month) to high (2%/month) bleeding risk will no longer benefit from the therapy after 3 or 2.5 months, respectively.In conclusion, our model supports the validity of the usually recommended duration of 3 months of oral anticoagulation after proximal vein thrombosis in the lower limbs, but suggests that this duration should be modulated between 2.5 and 4 months depending upon individual bleeding risk. Since clinical trials can hardly handle the complexity of the addressed issue, such a model may prove very helpful in daily clinical practice.

scholarly journals Management of Distal Deep Vein Thrombosis with Warfarin Versus Direct Oral Anticoagulant Agents

2021 ◽  
Vol 74 (4) ◽  
pp. e347
Author(s):  
Antoine Pham ◽  
Adele Heib ◽  
Emily Goodman ◽  
Ryan Cotto ◽  
John Denesopolis ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Oral Anticoagulant ◽  
Direct Oral Anticoagulant ◽  
Vein Thrombosis ◽  
Anticoagulant Agents ◽  
Distal Deep Vein Thrombosis ◽  
Deep Vein

Stratification of Venous Thromboembolism Risk in Ovarian Cancer Patients During Chemotherapy

2009 ◽  
Vol 19 (1) ◽  
pp. 79-83 ◽  
Author(s):  
Liliana Mereu ◽  
Saverio Tateo ◽  
Catherine Klersy ◽  
Eva Martinotti Gabellotti ◽  
Franco Polatti
Keyword(s):  
Ovarian Cancer ◽  
Deep Vein Thrombosis ◽  
Prognostic Factors ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
First Line ◽  
Susceptible Population ◽  
Vein Thrombosis ◽  
Multivariable Regression ◽  
Deep Vein

Background:The prevalence of venous thromboembolism (VTE) in ovarian cancer during first-line chemotherapy (CHT) ranges between 6.4% and 10.6%. Identification of the susceptible population is crucial for effective thromboprophylaxis.Methods:We performed a retrospective study of all our patients with epithelial ovarian cancer who underwent ambulatory first-line CHT between 1990 and 2004. Data were collected regarding age, body mass index (BMI), previous deep vein thrombosis, pulmonary embolism (PE), menopause status, FIGO stage, grade, histology, type of surgery, residual disease, and CHT. Univariable and multivariable regression analyses were performed to assess independent prognostic factors for VTE/PE to calculate a prognostic index (PI).Results:Of 203 patients, 16 (7.8%) had symptomatic VTE: 15 deep vein thrombosis and 1 PE. Multivariable regression analysis found that age (P = 0.01), BMI (P = 0.01), and stage (P = 0.05) were independent prognostic factors for VTE. Age, BMI, and stage were used to calculate the PI: 0.285 × age + 0.555 × BMI + 1.110 × stage. The PI was dichotomized according to its median cutoff (5.8) to define a low (3.8% at 6 months) and a high (11.3%) VTE incidence group.Conclusions:Age, BMI, and stage permit to identify ovarian cancer patients with a high risk in developing symptomatic VTE during CHT.

scholarly journals Clinical Experience of Direct Oral Anticoagulant in Patients with Deep Vein Thrombosis

2018 ◽  
Vol 29 (1) ◽  
pp. 13-19
Author(s):  
Kiyoaki Niimi ◽  
Akio Koyama ◽  
Yohei Kawai ◽  
Naohiro Akita ◽  
Takayuki Fujii ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Clinical Experience ◽  
Oral Anticoagulant ◽  
Direct Oral Anticoagulant ◽  
Vein Thrombosis ◽  
Deep Vein
Sign in / Sign up

Export Citation Format

Share Document